Summary:
- Two large-scale Phase 3 clinical trials demonstrated that an experimental drug for multiple sclerosis (MS) showed superior efficacy in reducing relapse rates compared to a currently approved standard-of-care therapy.
- The findings suggest a potential advancement in neuroimmunology, as the experimental treatment appears to offer improved clinical outcomes for patients managing relapsing forms of MS.